orphan drugs Archives -

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the

Evaluate’s Orphan Drug Report shows rapid acceleration in the space

https://pharmaphorum.com/market-access-2/evaluates-orphan-drug-report-2022/

Market Access/ Rare diseases/ Views & Analysis/ Views and analysis

Orphan drugs’ financial success raises questions

Ben Hargreaves drug prices, orphan drugs, Rare diseases 0 Comment

R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that

Orphan drugs’ financial success raises questions

https://pharmaphorum.com/market-access-2/orphan-drugs-financial-success-raises-questions/

Young attractive female scientist holding a red transparent pill

R&D/ Views & Analysis/ Views and analysis

Drug development and working with specialised Rare Disease networks

mike.smith@pharmaphorum.com genomics, IQVIA, orphan drugs, rare disease 0 Comment

There are currently an estimated 300 million people living with one or more Rare Diseases across the world.

Drug development and working with specialised Rare Disease networks

https://pharmaphorum.com/r-d/drug-development-working-specialised-rare-disease-networks/

R&D/ Views & Analysis/ Views and analysis/ Webinars/ Webinars in home page/ Webinars On demand

The power of R&D collaborations to improve outcomes in rare diseases

mike.hammerton@pharmaphorum.com genomic medicine, IQVIA, orphan drugs, precision medicine, Rare diseases 0 Comment

Far more common than initially thought, rare disease treatments remain far too scarce. The answer to the problem,

The power of R&D collaborations to improve outcomes in rare diseases

https://pharmaphorum.com/webinars/pharma-research-outcomes-rare-diseases/

Market Access/ Views & Analysis/ Views and analysis

How does HTA for orphan drugs differ across Europe?

George Underwood England, Europe, France, Germany, HTA, NICE, orphan drugs, Rare diseases, Scotland, SMC, UK 0 Comment

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines

How does HTA for orphan drugs differ across Europe?

https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/

The biggest challenges in rare disease drug development – and how the industry is fighting them

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

The biggest challenges facing rare disease pharma – and how the industry can tackle them

George Underwood Cambridge Rare Disease Network, orphan drugs, pricing, Rare Disease Day, Rare diseases 0 Comment

As Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers

The biggest challenges facing rare disease pharma – and how the industry can tackle them

https://pharmaphorum.com/r-d/views-analysis-r-d/biggest-challenges-rare-disease/

Partner content/ Press releases

Exclusive Bionical EMAS speaker interview released for Orphan Drugs & Rare Diseases

ssapal@smi-online.co.uk orphan drugs, Orphan Drugs development, patients access in orphan drugs, rare disease treatments, Rare diseases 0 Comment

Exclusive Bionical EMAS speaker interview released

Exclusive Bionical EMAS speaker interview released for Orphan Drugs & Rare Diseases

https://pharmaphorum.com/partner-content/exclusive-bionical-emas-speaker-interview-released-for-orphan-drugs-rare-diseases/

Sales and Marketing/ Views & Analysis/ Views and analysis

Who will be the biggest pharma players in orphan drugs?

George Underwood Amgen, AstraZeneca, Biogen, GlobalData, orphan disease, orphan drugs, rare disease, Roche, Sanofi, Takeda 0 Comment

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with

Who will be the biggest pharma players in orphan drugs?

https://pharmaphorum.com/views-analysis-sales-marketing/who-will-be-the-biggest-pharma-players-in-orphan-drugs/

Partner content/ Press releases

Mike Page, Alexion Pharmaceuticals invite to SMi’s Orphan Drugs & Rare Diseases

ssapal@smi-online.co.uk artificial intelligence, biomarker, orphan drugs, patient access, Rare diseases 0 Comment

Mike Page, invite to Orphan Drugs & Rare Diseases

Mike Page, Alexion Pharmaceuticals invite to SMi’s Orphan Drugs & Rare Diseases

https://pharmaphorum.com/partner-content/mike-page-alexion-pharmaceuticals-invite-to-smis-orphan-drugs-rare-diseases/

Trending

orphan drugs

Login